161 related articles for article (PubMed ID: 32800318)
41. Response to "Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us?".
Luk CP; Parsons R; Lee YP; Hughes JD
Ann Pharmacother; 2014 Mar; 48(3):432. PubMed ID: 24586075
[No Abstract] [Full Text] [Related]
42. Comments on "Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us?".
Famularo G
Ann Pharmacother; 2014 Mar; 48(3):431. PubMed ID: 24586074
[No Abstract] [Full Text] [Related]
43. Common single nucleotide polymorphisms in transient receptor potential melastatin type 6 increase the risk for proton pump inhibitor-induced hypomagnesemia: a case-control study.
Hess MW; de Baaij JH; Broekman MM; Bisseling TM; Haarhuis BJ; Tan AC; Te Morsche RH; Hoenderop JG; Bindels RJ; Drenth JP
Pharmacogenet Genomics; 2017 Mar; 27(3):83-88. PubMed ID: 27926584
[TBL] [Abstract][Full Text] [Related]
44. Proton pump inhibitor use is not associated with cardiac arrhythmia in critically ill patients.
Chen KP; Lee J; Mark RG; Feng M; Celi LA; Malley BE; Danziger J
J Clin Pharmacol; 2015 Jul; 55(7):774-9. PubMed ID: 25655574
[TBL] [Abstract][Full Text] [Related]
45. Diuretic-associated hypomagnesaemia.
Sheehan J; White A
Br Med J (Clin Res Ed); 1982 Oct; 285(6349):1157-9. PubMed ID: 6812785
[TBL] [Abstract][Full Text] [Related]
46. Potentially modifiable factors of dofetilide-associated risk of torsades de pointes among hospitalized patients with atrial fibrillation.
Naksuk N; Sugrue AM; Padmanabhan D; Kella D; DeSimone CV; Kapa S; Asirvatham SJ; Lee HC; Ackerman MJ; Noseworthy PA
J Interv Card Electrophysiol; 2019 Mar; 54(2):189-196. PubMed ID: 30353374
[TBL] [Abstract][Full Text] [Related]
47. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study.
Houltz B; Darpö B; Edvardsson N; Blomström P; Brachmann J; Crijns HJ; Jensen SM; Svernhage E; Vallin H; Swedberg K
Pacing Clin Electrophysiol; 1998 May; 21(5):1044-57. PubMed ID: 9604236
[TBL] [Abstract][Full Text] [Related]
48. Extreme but not life-threatening QT interval prolongation? Take a closer look at the neck!
Rentoukas E; Lazaros G; Sotiriou S; Athanassiou M; Tsiachris D; Deftereos S; Stefanadis C
J Electrocardiol; 2013; 46(2):128-30. PubMed ID: 23399054
[TBL] [Abstract][Full Text] [Related]
49. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study.
Kieboom BC; Kiefte-de Jong JC; Eijgelsheim M; Franco OH; Kuipers EJ; Hofman A; Zietse R; Stricker BH; Hoorn EJ
Am J Kidney Dis; 2015 Nov; 66(5):775-82. PubMed ID: 26123862
[TBL] [Abstract][Full Text] [Related]
50. Prevalence and risk factors of long-term proton pump inhibitors-associated hypomagnesemia: a cross-sectional study in hospitalized patients.
Recart DA; Ferraris A; Petriglieri CI; Alonso Serena M; Bonella MB; Posadas-Martinez ML
Intern Emerg Med; 2021 Apr; 16(3):711-717. PubMed ID: 33001349
[TBL] [Abstract][Full Text] [Related]
51. [Acquired long QT syndrome].
Zürcher JP; Schlaepfer J; Waeber G; Pasquier M
Rev Med Suisse; 2013 Aug; 9(395):1538-42. PubMed ID: 24024425
[TBL] [Abstract][Full Text] [Related]
52. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients.
Khan Q; Ismail M; Haider I; Ali Z
J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):109-115. PubMed ID: 29458991
[TBL] [Abstract][Full Text] [Related]
53. Proton pump inhibitors and risk of hypomagnesemia.
Pasina L; Zanotta D; Puricelli S; Djignefa DC; Bonoldi G
Eur J Intern Med; 2015 Sep; 26(7):e25-6. PubMed ID: 26165831
[No Abstract] [Full Text] [Related]
54. Serum magnesium and proton-pump inhibitors use: a cross-sectional study.
Faulhaber GA; Ascoli BM; Lubini A; Mossmann M; Rossi G; Geib G; Furlanetto TW
Rev Assoc Med Bras (1992); 2013; 59(3):276-9. PubMed ID: 23680271
[TBL] [Abstract][Full Text] [Related]
55. Extreme hypomagnesemia: characteristics of 119 consecutive inpatients.
Cheminet G; Clain G; Jannot AS; Ranque B; Passeron A; Michon A; De Luna G; Diehl JL; Oudard S; Cellier C; Karras A; Vedié B; Prot-Bertoye C; Pouchot J; Arlet JB
Intern Emerg Med; 2018 Dec; 13(8):1201-1209. PubMed ID: 29951810
[TBL] [Abstract][Full Text] [Related]
56. Correction of thiazide-induced hypomagnesemia by potassium-magnesium citrate from review of prior trials.
Pak CY
Clin Nephrol; 2000 Oct; 54(4):271-5. PubMed ID: 11076102
[TBL] [Abstract][Full Text] [Related]
57. Torsade de Pointes Due to QT Prolongation after Pulmonary Vein Isolation for Persistent Atrial Fibrillation.
Chikata A; Kato T; Usuda K; Fujita S; Otowa KI; Maruyama M; Hayashi K; Takamura M
Intern Med; 2021 Jul; 60(13):2089-2092. PubMed ID: 33518578
[TBL] [Abstract][Full Text] [Related]
58. [Atrial fibrillation, heart failure and QT interval prolongation -- diastolic and therapeutic difficulties].
Stec S; Zaborska B; Makowska E
Kardiol Pol; 2006 Jan; 64(1):87-90; discussion 91-2. PubMed ID: 16444640
[TBL] [Abstract][Full Text] [Related]
59. Clinical hypomagnesemia, coronary spasm and cardiac arrhythmia.
Chadda KD
Magnesium; 1986; 5(1):47-52. PubMed ID: 3959598
[TBL] [Abstract][Full Text] [Related]
60. Lansoprazole-induced hypomagnesaemia.
Krupa LZ; Fellows IW
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24414180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
